252 related articles for article (PubMed ID: 26602014)
1. Hormonal manipulation with toremifene in sporadic desmoid-type fibromatosis.
Fiore M; Colombo C; Radaelli S; Callegaro D; Palassini E; Barisella M; Morosi C; Baldi GG; Stacchiotti S; Casali PG; Gronchi A
Eur J Cancer; 2015 Dec; 51(18):2800-7. PubMed ID: 26602014
[TBL] [Abstract][Full Text] [Related]
2. Toremifene: an evaluation of its safety profile.
Harvey HA; Kimura M; Hajba A
Breast; 2006 Apr; 15(2):142-57. PubMed ID: 16289904
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene.
Taneja SS; Morton R; Barnette G; Sieber P; Hancock ML; Steiner M
J Clin Oncol; 2013 Feb; 31(5):523-9. PubMed ID: 23295793
[TBL] [Abstract][Full Text] [Related]
4. Stabilization and regression of a recurrent desmoid tumor with the antiestrogen toremifene.
Maseelall P; Robins JC; Williams DB; Thomas MA
Fertil Steril; 2005 Aug; 84(2):509. PubMed ID: 16086575
[TBL] [Abstract][Full Text] [Related]
5. Phase II and III clinical trials of toremifene for metastatic breast cancer.
Vogel CL
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):9-13. PubMed ID: 9556785
[TBL] [Abstract][Full Text] [Related]
6. Correlation between tumor growth and hormonal therapy with MR signal characteristics of desmoid-type fibromatosis: A preliminary study.
Gondim Teixeira PA; Chanson A; Verhaeghe JL; Lecocq S; Louis M; Hossu G; Blum A
Diagn Interv Imaging; 2019 Jan; 100(1):47-55. PubMed ID: 30037746
[TBL] [Abstract][Full Text] [Related]
7. Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer.
Milla-Santos A; Milla L; Rallo L; Solano V
Breast Cancer Res Treat; 2001 Jan; 65(2):119-24. PubMed ID: 11261827
[TBL] [Abstract][Full Text] [Related]
8. Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor.
Yamamoto Y; Masuda N; Ohtake T; Yamashita H; Saji S; Kimijima I; Kasahara Y; Ishikawa T; Sawaki M; Hozumi Y; Iwase H
Breast Cancer; 2010 Oct; 17(4):254-60. PubMed ID: 19685269
[TBL] [Abstract][Full Text] [Related]
9. Phase III randomized trial of toremifene versus tamoxifen for Japanese postmenopausal patients with early breast cancer.
Kimura M; Tominaga T; Kimijima I; Takatsuka Y; Takashima S; Nomura Y; Kasumi F; Yamaguchi A; Masuda N; Noguchi S; Eshima N
Breast Cancer; 2014 May; 21(3):275-83. PubMed ID: 22968626
[TBL] [Abstract][Full Text] [Related]
10. Low-grade endometrial stromal sarcoma developing in a postmenopausal woman under toremifene treatment for breast cancer.
Kashiyama T; Oda K; Kawana K; Arimoto T; Kanetaka Y; Takazawa Y; Maeda D; Nakagawa S; Yano T; Kozuma S
J Obstet Gynaecol Res; 2013 Jan; 39(1):424-9. PubMed ID: 22690656
[TBL] [Abstract][Full Text] [Related]
11. Long-term Efficacy of Methotrexate Plus Vinblastine/Vinorelbine in a Large Series of Patients Affected by Desmoid-Type Fibromatosis.
Palassini E; Frezza AM; Mariani L; Lalli L; Colombo C; Fiore M; Messina A; Casale A; Morosi C; Collini P; Stacchiotti S; Casali PG; Gronchi A
Cancer J; 2017; 23(2):86-91. PubMed ID: 28410293
[TBL] [Abstract][Full Text] [Related]
12. Potential role of the steroid receptor pattern in the response of inoperable intra-abdominal desmoid to toremifene after failure of tamoxifen therapy.
Altomare DF; Rotelli MT; Rinaldi M; Bocale D; Lippolis C; Lobascio P; Cavallini A
Int J Colorectal Dis; 2010 Jun; 25(6):787-9. PubMed ID: 20012438
[No Abstract] [Full Text] [Related]
13. Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer.
Lewis JD; Chagpar AB; Shaughnessy EA; Nurko J; McMasters K; Edwards MJ
Cancer; 2010 May; 116(10):2307-15. PubMed ID: 20209619
[TBL] [Abstract][Full Text] [Related]
14. Toremifene for breast cancer: a review of 20 years of data.
Vogel CL; Johnston MA; Capers C; Braccia D
Clin Breast Cancer; 2014 Feb; 14(1):1-9. PubMed ID: 24439786
[TBL] [Abstract][Full Text] [Related]
15. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment.
Fiore M; Rimareix F; Mariani L; Domont J; Collini P; Le Péchoux C; Casali PG; Le Cesne A; Gronchi A; Bonvalot S
Ann Surg Oncol; 2009 Sep; 16(9):2587-93. PubMed ID: 19568815
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of apatinib for patients with advanced extremity desmoid fibromatosis: a retrospective study.
Zheng C; Fang J; Wang Y; Zhou Y; Tu C; Min L
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2127-2135. PubMed ID: 33452581
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of high-dose toremifene as a second-line hormone therapy in patients with advanced or metastatic breast cancer resistant to aromatase inhibitor].
Kubota O; Onuki Y; Uchiyama T; Oishi K; Takeda M
Gan To Kagaku Ryoho; 2012 May; 39(5):753-7. PubMed ID: 22584326
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Physician's Systemic Treatment Preferences for Patients with Advanced Desmoid-Type Fibromatosis: Experience-Based Medicine in the Absence of High-Level Evidence.
Schöffski P; Requilé A; van Cann T
Oncol Res Treat; 2018; 41(4):214-219. PubMed ID: 29562221
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of sporadic and FAP-associated desmoid tumors treated with high-dose selective estrogen receptor modulators and sulindac: a single-center long-term observational study in 134 patients.
Quast DR; Schneider R; Burdzik E; Hoppe S; Möslein G
Fam Cancer; 2016 Jan; 15(1):31-40. PubMed ID: 26275868
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of estrogen receptor-beta in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients.
Cappelletti V; Celio L; Bajetta E; Allevi A; Longarini R; Miodini P; Villa R; Fabbri A; Mariani L; Giovanazzi R; Galante E; Greco M; Grazia Daidone M
Endocr Relat Cancer; 2004 Dec; 11(4):761-70. PubMed ID: 15613450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
